X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7572) 7572
Magazine Article (73) 73
Book / eBook (16) 16
Publication (6) 6
Book Review (5) 5
Web Resource (5) 5
Conference Proceeding (4) 4
Streaming Video (2) 2
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6933) 6933
antiparkinson agents - therapeutic use (6352) 6352
parkinson disease - drug therapy (4995) 4995
male (4028) 4028
female (3613) 3613
parkinson's disease (3366) 3366
middle aged (3138) 3138
levodopa - therapeutic use (3090) 3090
clinical neurology (3078) 3078
aged (3040) 3040
antiparkinson agents - adverse effects (1995) 1995
neurosciences (1905) 1905
parkinson disease - physiopathology (1576) 1576
levodopa (1516) 1516
animals (1408) 1408
adult (1274) 1274
levodopa - adverse effects (1108) 1108
parkinson disease - complications (1045) 1045
pharmacology & pharmacy (1027) 1027
antiparkinson agents - administration & dosage (1014) 1014
neurology (1011) 1011
treatment outcome (992) 992
antiparkinson agents - pharmacology (944) 944
dopamine (770) 770
drug therapy, combination (740) 740
parkinson disease - therapy (733) 733
aged, 80 and over (718) 718
dopamine agonists - therapeutic use (683) 683
psychiatry (671) 671
parkinson’s disease (631) 631
severity of illness index (631) 631
l-dopa (609) 609
double-blind (607) 607
parkinson disease - psychology (606) 606
levodopa - administration & dosage (596) 596
parkinsons-disease (586) 586
parkinson disease - diagnosis (581) 581
dopa (579) 579
dose-response relationship, drug (553) 553
parkinsons disease (542) 542
time factors (526) 526
motor fluctuations (504) 504
rats (497) 497
basal ganglia (488) 488
double-blind method (468) 468
movement disorders (412) 412
deep brain stimulation (408) 408
analysis (406) 406
disease models, animal (404) 404
carbidopa - therapeutic use (400) 400
parkinson disease - metabolism (396) 396
medicine & public health (389) 389
disease (357) 357
dyskinesia (355) 355
parkinsonian disorders - drug therapy (353) 353
drug therapy (350) 350
dopamine - metabolism (339) 339
disease progression (331) 331
parkinson disease (329) 329
follow-up studies (327) 327
drug combinations (316) 316
therapy (307) 307
levodopa - pharmacology (306) 306
antiparkinson agents - pharmacokinetics (303) 303
care and treatment (297) 297
subthalamic nucleus (297) 297
motor activity - drug effects (285) 285
dyskinesia, drug-induced - etiology (278) 278
dementia (269) 269
dopamine agents - therapeutic use (265) 265
quality of life (263) 263
clinical trials as topic (256) 256
dopamine agonists - adverse effects (249) 249
risk factors (249) 249
magnetic resonance imaging (243) 243
brain (242) 242
neuropsychological tests (242) 242
antipsychotic agents - therapeutic use (237) 237
analysis of variance (234) 234
parkinson disease - epidemiology (232) 232
neurodegenerative diseases (231) 231
dyskinesia, drug-induced - drug therapy (230) 230
medicine, general & internal (229) 229
neuroprotective agents - therapeutic use (227) 227
antiparkinsonian agents (225) 225
diagnosis (222) 222
drug administration schedule (222) 222
parkinson disease - pathology (222) 222
research (219) 219
surgery (215) 215
pramipexole (204) 204
dopamine agonists (196) 196
retrospective studies (195) 195
antiparkinson agents (194) 194
mice (183) 183
deep brain-stimulation (181) 181
selegiline - therapeutic use (180) 180
prevalence (179) 179
dyskinesias (174) 174
neurons (171) 171
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6834) 6834
German (210) 210
French (170) 170
Spanish (159) 159
Russian (105) 105
Japanese (59) 59
Polish (35) 35
Dutch (28) 28
Italian (20) 20
Hungarian (18) 18
Chinese (14) 14
Danish (12) 12
Norwegian (10) 10
Portuguese (10) 10
Finnish (9) 9
Swedish (9) 9
Hebrew (7) 7
Czech (5) 5
Romanian (4) 4
Serbian (3) 3
Bosnian (1) 1
Icelandic (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 487 - 501
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D-3/D-2/D-1 dopamine receptor agonist... 
PLASMA-LEVELS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | CLINICAL-FEATURES | LONG-TERM TREATMENT | PATCH | AGONIST N-0437 | Thiophenes - therapeutic use | Restless Legs Syndrome - epidemiology | Thiophenes - adverse effects | Humans | Dopamine Agonists - therapeutic use | Tetrahydronaphthalenes - therapeutic use | Dopamine Agonists - adverse effects | Parkinson Disease - drug therapy | Thiophenes - administration & dosage | Tetrahydronaphthalenes - adverse effects | Restless Legs Syndrome - metabolism | Antiparkinson Agents - therapeutic use | Restless Legs Syndrome - drug therapy | Drug Interactions | Tetrahydronaphthalenes - administration & dosage | Parkinson Disease - epidemiology | Anti-Dyskinesia Agents - administration & dosage | Parkinson Disease - metabolism | Comorbidity | Dopamine Agonists - pharmacokinetics | Tetrahydronaphthalenes - pharmacokinetics | Evidence-Based Medicine | Antiparkinson Agents - adverse effects | Transdermal Patch - adverse effects | Antiparkinson Agents - pharmacokinetics | Anti-Dyskinesia Agents - therapeutic use | Thiophenes - pharmacokinetics | Animals | Anti-Dyskinesia Agents - adverse effects | Dopamine Agonists - administration & dosage | Antiparkinson Agents - administration & dosage | Anti-Dyskinesia Agents - pharmacokinetics | Practice Guidelines as Topic
Journal Article
Nutrition, ISSN 0899-9007, 2012, Volume 28, Issue 11, pp. 1081 - 1088
... of living cells. The use of synthetic antioxidants has decreased because of their suspected activity as carcinogenic promoters. We introduce a natural extract... 
Gastroenterology and Hepatology | Neuroprotection | Dopamine | Natural extract | Antioxidant | Recovery | OXIDATIVE STRESS | SUBSTANTIA-NIGRA NEURONS | LIPID-PEROXIDATION | STANDARDIZED EXTRACT | EGB761 PROTECTS | DOPAMINERGIC NEUROTOXICITY | NUTRITION & DIETETICS | SUPEROXIDE-DISMUTASE ACTIVITY | MONOAMINE-OXIDASE ACTIVITY | IN-VIVO | MOUSE CORPUS STRIATUM | Neuroprotective Agents - therapeutic use | Plant Extracts - chemistry | Antioxidants - chemistry | Oxidative Stress | Mesencephalon - metabolism | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Dietary Supplements - analysis | Antiparkinson Agents - therapeutic use | Dopaminergic Neurons - metabolism | Antiparkinson Agents - chemistry | Parkinson Disease - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Phytotherapy | Parkinson Disease - diet therapy | Disease Models, Animal | Neuroprotective Agents - chemistry | Antiparkinson Agents - adverse effects | Antioxidants - therapeutic use | Parkinson Disease - prevention & control | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antioxidants - adverse effects | Plant Extracts - therapeutic use | Apoptosis | Plant Extracts - adverse effects | Drugs | Antioxidants | Parkinson's disease | Neurons | Analysis | Medicine, Botanic | Medicine, Herbal | Health aspects | Isoflavones | Studies | Oxidative stress | Chinese medicine | Neurotoxicity | Free radicals | Acids | Neurodegeneration | Rodents | Dementia | Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 7, pp. 610 - 622
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2007, Volume 29, Issue 9, pp. 1825 - 1849
... Pharmacol 60 343-349, 1977. Tabakman R, Lecht S, Lazarovici P: Neuroprotection by monoamine oxidase B inhibitors . A therapeutic strategy for Parkinson's disease... 
Internal Medicine | Medical Education | rasagiline | Parkinson's disease | propargylamine | neuroprotection | monoamine oxidase | selegiline | CONTROLLED-TRIAL | SEROTONIN SYNDROME | MAO-B INHIBITOR | MPTP-INDUCED NEUROTOXICITY | MOTOR FLUCTUATIONS | MITOCHONDRIAL PERMEABILITY TRANSITION | IN-VIVO | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | L-DEPRENYL | NEUROBLASTOMA SH-SY5Y CELLS | rasagilme | Indans - adverse effects | Neuroprotective Agents - therapeutic use | Antiparkinson Agents - pharmacology | Humans | Selegiline - pharmacology | Parkinson Disease - drug therapy | Indans - therapeutic use | Monoamine Oxidase Inhibitors - administration & dosage | Antiparkinson Agents - therapeutic use | Drug Interactions | Neuroprotective Agents - pharmacology | Indans - administration & dosage | Neuroprotective Agents - adverse effects | Drug Therapy, Combination | Neuroprotective Agents - administration & dosage | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Selegiline - adverse effects | Monoamine Oxidase Inhibitors - adverse effects | Food-Drug Interactions | Antiparkinson Agents - adverse effects | Selegiline - administration & dosage | Antiparkinson Agents - administration & dosage | Indans - pharmacology | Oxidases | Medical colleges | Drug therapy | Analysis
Journal Article
Journal of Neurology, Neurosurgery & Psychiatry, ISSN 0022-3050, 08/2014, Volume 85, Issue 8, pp. 840 - 844
Journal Article